Lamivudin Mylan

Lamivudine, the active ingredient in Lamivudin Mylan, is a nucleoside reverse transcriptase inhibitor presented as an oral tablet for oral use. It treats human immunodeficiency virus (HIV) infection and chronic hepatitis B virus (HBV) infection in adult patients.

GNH USA supplies Lamivudin Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudin Mylan is an antiretroviral nucleoside analogue used to manage viral infections that rely on reverse transcription.

- HIV infection: reduces plasma HIV‑RNA levels and helps restore immune function. - Chronic hepatitis B infection: suppresses HBV DNA replication and lowers liver inflammation. - HIV/HBV co‑infection: provides simultaneous control of both viruses in patients with dual infection.

Lamivudin Mylan may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Fatigue: generalized tiredness. - Diarrhoea: loose stools.

Serious or Rare Side Effects: - Lactic acidosis: severe metabolic disturbance requiring immediate medical attention. - Hepatotoxicity: significant liver enzyme elevation or failure. - Pancreatitis: inflammation of the pancreas with abdominal pain. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hypersensitivity: rash, fever, or organ involvement.

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor for adverse events.

- Liver function monitoring: check transaminases regularly, especially in patients with pre‑existing liver disease. - Renal function assessment: adjust dosing if creatinine clearance is reduced. - Mitochondrial toxicity vigilance: watch for signs of lactic acidosis or hepatic steatosis. - Adherence counseling: emphasize the importance of consistent dosing to prevent resistance. - Hypersensitivity awareness: discontinue if severe rash or systemic reaction occurs. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lamivudin Mylan can affect, or be affected by, several concomitant medicines.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis and peripheral neuropathy. - Stavudine: heightened mitochondrial toxicity.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce lamivudine plasma concentrations. - Antacids containing aluminium or magnesium: can lower absorption; separate dosing by at least 2 hours. - Warfarin: monitor INR as lamivudine may potentiate anticoagulant effect.